/
ELVN
$58.06+$0.14 (+0.24%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.2B
73M shares
52-week range
$14.79 – $62.32
91% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$34.31
Enliven Therapeutics, Inc. Common Stock
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
www.enliventherapeutics.com- Employees
- 67
- IPO / List date
- Feb 24, 2023
- HQ
- BURLINGAME, CA
Held by traders on TradeandTell
No one on the platform currently holds ELVN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 59,000 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ELVN yet.
